Article
Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.
European journal of pharmacology - 5 Aug 2023
Wang Aoli, Liu Juan, Li Xixiang, Zou Fengming, Qi Ziping, Qi Shuang, Liu Qingwang, Wang Zuowei, Cao Jiangyan, Jiang Zongru, Wang Beilei, Ge Juan, Wang Li, Wang Wenchao, Liu Jing, Liu Qingsong
Abstract excerpt
Although rat sarcoma viral oncogene homolog (RAS) mutations occur in about 30% of solid tumors, targeting RAS mutations other than KRAS-G12C is still challenging. As an alternative approach, developing inhibitors targeting RAF, the downstream effector of RAS signaling, is currently one of the main strategies for cancer therapy. Selective v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-V600E inhibitors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.